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long-term hospitalisation due to severe pneumonia and performed a longitudinal in-depth 48 study of the composition of their lung microbiome by high-throughput Illumina sequencing of 49 the 16S rRNA gene (bacteria and archaea), ITS region (fungi) and 18S rRNA gene 50 (eukaryotes). We found that the composition of the bacterial lung microbiome during 51 pneumonia is hugely disturbed containing a very high percentage of the pathogen, a very low 52 bacterial diversity, and an increased presence of opportunistic microorganisms such as species 53 belonging to Staphylococcaceae and Streptococcaceae. The microbiome of antibiotic treated 54 patients cured from pneumonia represented a different perturbation state with a higher 55 abundance of resistant bacteria (mainly Firmicutes) and a significantly different bacterial 56 composition as that found in healthy individuals. In contrast, the mycobiome remains more 57 stable during pneumonia and antimicrobial therapy. Interestingly we identified possible 58
BACKGROUND 72
Historically the lower airways were thought to be sterile unless infected, however, the 73 development of culture-independent techniques and high-throughput sequencing have 74 revealed that the respiratory tract harbours like almost every mucosal surface in the human 75 body a distinct microbiome composed of bacteria, fungi and viruses [1] [2] [3] . In 2016, the 76 bacterial composition of the healthy lung was the first time deeply characterized by analysing 77 bronchoalveolar lavage fluid (BAL) samples from healthy individuals. Two types of 78 microbiome profiles (termed pneumotypes) were described [4] . One of the pneumotypes 79 named supraglottic predominant taxa (SPT) was characterized by a high bacterial load and the 80 presence of anaerobes such as Prevotella and Veillonella belonging to the phyla Firmicutes 81 and Bacteroidetes whereas the second pneumotype was called the background predominant 82 taxa (BPT) as it presented a low biomass and identified bacteria belonged mainly to the phyla 83 Proteobacteria, and Actinobacteria such as Acidocella or Pseudomonas. Although biology of 84 the lung microbiome is a new field and very little is known about its role in human health, it 85 was suggested that the lung microbiome participates in immune system functions including 86 immune cell maturation and inflammatory responses [2, 5] . Segal and colleagues proposed 87 that bacteria such as Prevotella and Veillonella that have been commonly identified in the 88 lungs of healthy individuals or their products participate in the regulation of inflammation and 89 are linked to the activation of the lung mucosal Th17 response [4] . 90
The healthy lung mycobiome is mainly composed of environmental fungi belonging to 91 the phyla Ascomycota and Basidiomycota such as Davidiellaceae, Eurotium Eremothecium, 92 and Cladosporium, while during disease a higher abundance of pathogenic species belonging 93 to the genera Aspergillus, Malassezia or Candida are present [6] . Commensal fungi, like 94 bacteria, seem to participate in immune system stimulation, inflammatory response and 95 protection against pathogens [5, 6] . In contrast to the lung micro-and mycobiome that starts 96 to be investigated better, the presence of eukaryotes, archaea and viruses among the lung 97 microbiota has been very little investigated like for most other body habitats. 98
To date, the majority of studies analysing the lung microbiome in disease have 99 focused on cystic fibrosis [7-9] asthma [10, 11] or chronic obstructive pulmonary disease 100 (COPD) [12] [13] [14] . These studies have shown that lung microbial dysbiosis is generally 101 characterized by a microbiome enriched in pathogenic and opportunistic bacteria (such as 102 certain Gammaproteobacteria), with a high biomass due to the overgrowth of pathogens and a 103 low diversity because of the displacement of the normal members of the community [2, 5] . 104 However, few studies have addressed the role of the microbiome composition during 105 infectious diseases in the lungs. 106
Acute lower respiratory tract infections are the leading cause of morbidity and 107 mortality worldwide among infectious diseases. Among these, pneumonia represents a 108 clinical and economic burden and a major public health problem, particularly for children and 109 the elderly. Legionella pneumophila is one of these human, bacterial pathogens as it is 110 causing a severe pneumonia called Legionnaires' disease that is often fatal when not treated 111 promptly. It is characterized by clinical polymorphism and variable severity, 98% of cases are 112 hospitalized and 40% require intensive care unit (ICU) admission. Here we report a comprehensive analysis of the lung microbiome composition of three 123 patients with long-term pneumonia due to L. pneumophila and its evolution during antibiotic 124 treatment. Using high-throughput sequencing of marker genes we show that the pulmonary 125 treatment was switched to a combination of erythromycin and levofloxacin [16, 17] (Figure  139 1A). During one month and a half of hospitalization and treatment the patient was sampled 140 intensively and due to the suspicion of the presence of a lung abscess according a thoracic 141 computed tomography scan (CT-SCAN), rifampicin was added at day 13. While the patient 142 remained febrile, a second thoracic CT-SAN indeed revealed a voluminous lung abscess at 143 day 34 and Fusobacterium nucleatum was identified in addition to L. pneumophila. Thus, 144 nitroimidazole was added for 20 more days. The abscess was resected at day 42 of treatment 145 and the patient recovered fully. Here we analysed the microbiome composition of BAL 146 samples taken at day 5, 14, 24, 34 and 42 post-admission as well as one sputum sample taken 147 at day 4 post-admission and a biopsy taken during the lung abscess removal at day 42 ( Figure  148 1A). 149 Patient B, a 69-year-old immunocompromised woman, was hospitalised for 150 pneumonia caused by Legionella and treated for 21 days with levofloxacin. After a period of 151 37 days free of symptoms, she was re-hospitalised for bilateral pulmonary consolidations and 152 pleural effusion. A recurrent Legionella caused pneumonia was confirmed and she was 153 treated for six weeks with a combination of erythromycin and levofloxacin and also 154 cotrimoxazole for a concomitant pneumocystosis [17] . A sample was taken at the onset of the 155 treatment (day 0) and after two months and a half (day 82) ( Figure 1B) . We analysed both 156 samples to study the composition of the microbial community composition at the beginning 157 and the end of the treatment. 158
Patient C, a 76-year-old immunocompromised man, was sampled 109 days after the 159 onset and 19 days after the end of the therapy when the patient was fully recovered; this BAL 160 was negative for L. pneumophila as confirmed by PCR [17] . Thus, this sample represents the 161 lung microbiome after an intensive antibiotic treatment (named C109) ( Figure 1C) . 162
To compare the pneumonia microbiomes with that of healthy lung microbiomes we 163 retrieved the raw data of a recent study published by Segal during the first 24 days of the antibiotic treatment (Figure 2A) . At the time of diagnosis 171
Legionella represented 99% of the identified bacteria in the lungs. After 10 days of adapted 172 treatment (day 14) Legionella was still responsible for around 80% of the bacterial 173 composition, followed by Enterococcus with a relative abundance of 13%. Interestingly, at 174 day 24 Legionella increased again to a relative abundance of 95% of the total amount of 175 bacteria. Similarly, the microbiome of patient B was mainly composed of Legionella 176 representing 57% of the diversity at the beginning of the treatment (Figure 2B) . Thus, 177 Legionella represents the vast majority (57-99%) of the bacterial community during infection 178 similar to what was shown for Pseudomonas aeruginosa infections [18, 19] . 179 180 Antibiotic treatment leads to strong perturbations and slow recovery of a healthy 181 microbiome. A strong change occurred in the microbiome composition of patient A between 182 day 24 and 34 probably due to the changed treatment (30 days after the beginning of 183 treatment and 20 days after adding rifampicin) (Figure 2A) . First, we found a marked 184 decrease in the relative abundance of Legionella, representing only around 20% of the 185 composition. Secondly, we found a recovery of the relative abundance of certain bacteria 186 commonly found in the lung microbiome of healthy individuals. Importantly, the abundance 187 of Prevotella changed from less than 1% during the first 24 days of therapy to around 50% at 188 day 34. Indeed, certain species of the genus Prevotella are resistant to different classes of 189 antibiotics including macrolides, which were included in the treatment [20] . Furthermore, 190 Prevotella was described as predominant taxa in healthy microbiomes [4] suggesting that the 191 microbiome started to recover. At day 33 additional normal bacteria of the lung microbiome 192 such as Staphylococcus (11%), Alloprevotella (6%) and Oribacterium (4%) were identified. 193
Finally, an increase in the abundance of Fusobacterium (14%) was observed. Interestingly, 194 F. nucleatum is ubiquitous in the oral cavity, but absent or rarely detected at other body sites 195 of healthy people. However, under disease conditions, this bacterium is one of the most 196 prevalent species found in extra-oral sites [21] . Erythromycin (macrolide) is also not effective 197 against Fusobacterium explaining the increase of its abundance in the last days of treatment 198 [22] . 199
The species richness of the different samples was estimated based on the number of 200 observed OTUs and the richness estimator Chao 1, while the species evenness was based on 201 the Shannon index. According to these metrics, the bacterial diversity collapsed due to the 202 antibiotic treatment around day 24 reaching the lowest values for all estimated parameters 203 (Supplementary figure 1A) . A collapse in bacterial diversity during antibiotic treatment has 204 also been described for other human microbial communities such as the gut [23, 24] . 205
The bacterial load analysis based on qPCR of the 16S rRNA gene showed a decrease 206 in biomass during the antibiotic treatment ( Figure 2C) . During the first days of treatment the 207 bacterial load was very high (10 10 -10 12 copies of the 16S rRNA gene) but after day 24 the 208 load decreased to 10 8 -10 9 probably due to the addition of rifampicin at day 13 and/or to the 209 time needed for activity of the combination of fluoroquinolone plus macrolide. The difference 210 between the days 5 and 14 compared to days 34 and 42 was statistically significant (Wilcoxon 211 signed-rank test p-value=0.002). Our Pearson correlation analysis between the Ct values of 212 L. pneumophila and the total biomass (16S rRNA data) pointed to a significant positive 213 correlation between both (p-value = 0.04) ( Figure 2D) . Thus, the decrease in biomass can be 214 partially explained by the decrease of the pathogen abundance due to the antibiotic therapy. 215
The lung microbiome of patient B showed a similar dynamics. At the beginning of the 216 long-term treatment (day 0) with several levofloxacin, erythromycin and cotrimoxazole, 217 ( Figure 1B) , the microbiome was mainly composed of Legionella (57%) and secondly of 218 Kingella (22%) and Capnocytophaga (7.6%) ( Figure 2B) , genera that are not reported to be 219 part of bacteria present in the healthy lungs [4] .. After two long periods of antibiotic treatment 220 (day 82) the composition changed dramatically, and the most abundant bacteria then were 221
Enterococcus (64%), Staphylococcus (14%), Campylobacter (4.5%) and Lactococcus (4.4%), 222 while the abundance of Legionella decreased to 0.2% and Kingella and Capnocytophaga were 223 not present anymore. The enrichment of Enterococcus after the treatment might be due to the 224 often-observed resistance of these bacteria to several different antibiotics including 225 fluoroquinolones, macrolides and cotrimoxazole, and as described for the gut [25], the 226 antibiotic treatment may also lead to the dissemination of enterococci in the lungs. 227 Furthermore, after antibiotic treatment we observed, like for patient A, an increase in 228
Staphylococcus, a genus reported to be frequently resistant to fluoroquinolones and 229 macrolides [26] . The species evenness based on the Shannon index was higher during 230 infection than after treatment, but like for patient A, the species richness was higher at the end 231 of the infection (Supplementary Figure 1B) . 232
233
During bacterial pneumonia and antibiotic therapy the mycobiome is less disturbed 234 than the microbiome. The mycobiome composition during long-term legionellosis and 235 antibiotic treatment (Patient A) showed different dynamics than the microbial composition. 236
The fungal microbiome fraction was mainly composed of species belonging to the phyla 237 Basidiomycota, and Ascomycota ( Figure 3A) . These two phyla are reported to be the most 238 abundant ones in the human respiratory tract [6] . The major taxa that we identified during the 239 entire sampling period were unclassified species belonging to Agaricomycetes (16-50%), 240
Ascomycota (20-44%), Agaricales (10-18%) and Basidiomycota (8-16%). This indicates that 241 a high diversity of fungi from the human mycobiome remains unknown and awaits 242 characterisation. Some of the most abundant genera identified were Candida (0.8-7%) and 243
Morchella (0.4-3.5%) (Ascomycota) and Malassezia (0.2-4%) (Basidyomycota). Despite the 244 higher homogeneity of the mycobiome composition, the richness and diversity of the fungal 245 species showed a parallel dynamics as it decreased also through the antibiotic treatment, 246 reaching the minimum at day 24th of treatment similar to the microbiome (Supplementary 247 figure 2A ). Again, as seen for the bacterial fraction the fungal diversity started to recover by 248 day 34 of the treatment. The changes in the mycobiome during bacterial infection and 249 antibiotic treatment suggest that the fungal and the bacterial communities interact ecologically 250 in the lungs (i.e. cooperation, competition) and with the host immune system and the 251 inflammatory responses. Indeed, in a mouse model of oropharyngeal candidiasis a potential 252 mutualism has been reported where the main pathogen Candida albicans promotes mucosal 253 biofilm formation and colonization of Streptococcus oralis through modulation of the mouse 254 inflammatory response, thus increasing the virulence of the infection [27] . Also, C. albicans 255 favours the growth of Pseudomonas aeruginosa during pneumonia by affecting the 256 production of reactive oxygen species (ROS) by alveolar macrophages in rats [28] . Thus, also 257 in the human lung the displacement of some key microorganisms in the microbial community 258 due to infection and treatment may affect the survival of other microorganisms that depend on 259 them. 260
These results were confirmed by the analyses of the mycobiome of patient B. Before 261 antibiotic treatment the genus Candida showed a relative abundance of 65% and unclassified 262 fungi from the class Agaricomycetes and Basidiomycota a relative abundance of 11% and 263 7%, respectively ( Figure 3B ), but after several weeks of antibiotic treatment (day 82) about 264 99% of the sequences belonged to the genus Candida. In parallel to the marked increase of 265 Candida, the diversity values (the number of observed OTUs, Chao 1 and Shannon index) 266 were lower after antibiotic therapy (Supplementary Figure 2B) . Indeed, increase in the 267 abundance of Candida has often been associated to extensive antibiotic usage in hospitals 268 [29] , similar to what was seen here. Thus, infection and associated antibiotic treatment 269 changes the healthy lung microbiome considerably, and allows Candida species to occupy the 270 niche, which is disturbed by the pathogen and the antibiotics treatment. 271 272 BALs represent the lung microbiome composition with higher accuracy than sputum. 273
We compared the BAL sample taken at day 5 with the sputum sample taken at day 4 to 274 compare the difference in the composition (patient A). The most abundant bacterial genera in 275 the sputum were Streptococcus (43%), Prevotella (13%) and Gemella (13%) while Legionella 276 represented only 3% of the total relative abundance ( Figure 4A) . In contrast, the BAL sample 277 showed a lower diversity and OTU richness since more than 99% of the sequences belonged 278
to Legionella (Supplementary figure 1A) . This reveals that during pneumonia the presence 279 of Legionella is minimal in the sputum while Legionella is abundant in the BAL samples that Agaricomycetes (30%), and Candida (11%) as these were enriched in the sputum sample. 287
However, the alpha-diversity measures were lower in the sputum than in the BAL sample 288 ( Supplementary figure 2A) suggesting that bronchoscopy is a more accurate technique for 289 the study of the fungal diversity of the lungs at species level. 290
291
The lung abscess is enriched in pathogenic microorganisms. One of the reasons why 292 patient A did not recover for such a long time despite antibiotic treatment, was probably the 293 presence of a lung abscess that was confirmed only at day 34 and which may have shed 294
Legionella constantly into the lungs. We thus characterized also the microbial composition of 295 the lung abscess that was resected by surgery (day 42) ( Figure 5A ). It was mainly composed 296 of Legionella (38%), followed by Prevotella (19%), Fusobacterium (15%) and Oribacterium 297 (15%). As expected, Legionella was more abundant in the lung abscess than in the BAL 298 samples. In contrast, anaerobic bacteria such as Fusobacterium, Oribacterium, Shuttleworthia 299 showed higher abundance in the abscess as the environment is more anoxic [30] , but the 300 species richness was lower as less species seemed to be able to colonize the abscess 301 (Supplementary figure 1A) . 302
The fungal composition of the lung abscess ( Figure 5B ) was dominated by Candida 303 (50% of the relative abundance) and other fungal genera belonging to the Ascomycota (20%) 304 revealing enrichment in the relative abundance of this phylum. The species richness was 305 higher in the lung abscess but the Shannon Index was lower as few species were dominant 306 ( Supplementary figure 2A) . In in vitro models it has been shown that C. albicans and 307
Fusobacterium strongly co-aggregate [31, 32] . Thus, Candida may take advantage of the 308 presence of bacterial pathogens such as F. nucleatus that was highly abundant in the abscess. 309
Indeed, co-infection in lung abscess of Candida and bacteria has been previously reported 310
[33] suggesting that the high abundance of Candida is related to the infection with Legionella 311 and the presence of Fusobacterium. 312 313 After long-term antibiotic treatment the microbiome is enriched in Firmicutes and 314 starts to recover. To analyse the recovery of the microbiome after L. pneumophila induced 315 pneumonia and the associated antibiotic treatment we characterized the lung microbiome 316 composition of patient C three weeks after the end of two episodes of antibiotic treatment 317 (spiramycin, levofloxacin, azithromycin) before and after a 55 days symptom-free interval, 318
( Figure 1C ) defined as day 0 after the end of the treatment. 319
The bacterial composition was enriched in Firmicutes such as Streptococcus (20%), 320
Prevotella (17%), Veillonella (15%) and Enterococus (10%) (Figure 6A) . The presence of 321
Prevotella and Veillonella has been identified in the lungs of healthy people suggesting that 322 the lung microbiome of this patient was in the restoration process [4] . The mycobiome was 323 mainly composed of unclassified fungi belonging to the phyla Ascomycota (40%), 324 Basidiomycota (38%) and Agaricomycetes phyla (14%), a fungal composition similar to a 325 healthy microbiome (Figure 6B) . Similarly, to the samples from patient B the species 326 evenness (Shannon=4.9) and OTU richness (Chao 1=2348, number of OTUs= 990) after 327 treatment were higher, compared to the samples from patient A and B during infection. 328 Archaea are present in the lung microbiota during infection and antibiotics therapy. As 329 it was recently reported that archaea seem to be present at all body sites including the nose 330 and lung [34], we analysed the archaea composition in the samples of the patients of this 331 study. We used primers 787F/1000R that amplify a 16S rRNA gene region that were 332 specifically designed for archaea detection but that also amplify bacterial rRNA [35] . Thus, 333 for all the samples we obtained a mixture of bacterial and archaeal reads. The proportion of 334 bacteria and archaea was very variable between samples ( Supplementary Table 1 ) as the 335 bacterial proportion ranged from 27 to 98% reads (average of 57%), and the archaeal 336 proportion from 2 to 72% reads (average of 43%). After filtering the bacterial reads and 337 classification (0.5 criteria of bootstrap) in average 45% of the sequences were retained. The 338 most abundant archaea identified in all the patients was Methanobrevibacter representing 339 more than 50% of the archaeal diversity in all the samples ( Supplementary Table 2 ). 340
Patients A and C carried also other unclassified Euryarchaeota and Thermoprotei 341 (Crenarchaeota), while in patient C only archaea belonging to the genus Methanobrevibacter 342 were identified. The closest species of the most abundant OTUs was Methanobrevibacter 343 smithii, which was surprising as it is described as an anaerobic methane producing archaea. It 344 was reported to be present mainly in the human gut, however recently it was also found in the 345 nose, lungs and on the skin [34]. Thus, it is possible that also in the lung environment there 346 might be some anaerobic niches, or that other bacteria present in the lung help this anaerobic 347 archaeon to grow in the lungs. Indeed, aerobic culture of methanogenic archaea without an 348 external source of hydrogen has been reported when Bacteroides thetaiotaomicron, which 349 produces hydrogen was present [36] . The presence of archea in all our samples can be related 350 to the fact that the archaea are generally resistant to most of the antibiotics [37, 38] . 351
Interestingly, methanogenic archaea have been associated with different diseases suggesting 352 that this group of archaea may contribute to the disease in specific conditions and thus, 353 perhaps also during pneumonia [34] . the human contamination was too high to correctly analyse the data (data not shown). Thus, 361
we analysed the presence of the genus Acanthamoeba a natural host of Legionella and 362 laboratory model amoeba, and the class Heterolobosea that contains many of the known 363 amoebal hosts of Legionella, with primers that are more specific for amoeba. Indeed, this 364 allowed detecting the genus Acanthamoeba ( Supplementary Table 3 
) and the genus 365
Trichomonas in all the samples analysed (Supplementary Table 4) . Most of the OTUs of the 366 genus Acanthamoeba belonged to the species Acanthamoeba castellani, which is a natural 367 host of Legionella. The most abundant OTU identified was close to Trichomonas tenax a 368 protozoa commonly found in the human oral cavity that is also rarely associated with 369 pulmonary infections [40] . Furthermore, a very high presence of unclassified eukaryotes was 370 identified, suggesting that a large fraction of the eukaryotic diversity present in the lungs 371 remains unknown (Supplementary Tables 3 and 4) . Further studies using different genus-372 specific primers and samples from healthy individuals will allow to learn whether there is a 373 community of resident protozoa in the lungs or if they are specifically associated to 374
Legionella caused pneumonia. 375
376
The lung microbiome during Legionella infection and antimicrobial therapy is 377 significantly different from a healthy microbiome. To better understand the differences 378 between the lung microbiome composition of healthy individuals and the lung microbiome 379 influenced by infection and antibiotic treatment, we compared the healthy microbiomes 380 reported by Segal and colleagues, 2016 [4] with our patient samples. We first reanalysed the 381 49 published BAL samples using our analyses pipeline. This confirmed the two groups 382 described by the authors. Figure 3) . 387
The comparison showed, that the lung microbiome composition of the healthy people 388 and the pneumonia patients were significantly different when applying the ADONIS test (p-389 value=0.004975). Also, cluster analyses clustered the microbiomes of the pneumonia patient 390 separately from the two healthy pneumotypes (Figure 7A) . Furthermore, the samples 391 containing a high abundance of Legionella clustered together, while the two microbiomes 392 analysed after the antibiotic treatment (one from patient B and the one from patient C) were 393 different. However, they were also different from the healthy microbiomes. 394
We used the linear discriminant analysis (LDA) effect size (LEfSe) analysis and 395 compared statistically the two pneumotypes (healthy microbiome) with the infected or the 396 antibiotics treated samples (disrupted microbiome) (Supplementary table 5) . This revealed 397 that a total of 34 families of which the majority belonged to the phyla Proteobacteria, were 398 more abundant in microbiome samples of healthy people. The most significant ones were 399 Xanthomonadaceae, Acetobacteraceae, Sphingomonadaceae, abundant OTUs from each of these families. Some species may take advantage of the host 410 inflammatory responses that is induced by infection. For example, it has been shown that the 411 generation of intra-alveolar catecholamines and inflammatory cytokines alters the microbial 412 growth conditions thereby favouring specific bacterial groups during lung infections 413
including Streptococcus [41] . Furthermore, a retrospective study showed that Streptococcus 414 sanguinis is an important agent associated with lung abscess development ("Jerng(1997) ," 415 n.d.), a OTU that was highly abundant also in our abscess sample (40%) suggesting that this 416 might be a general feature of lung abscess. 417
When the Wilcoxon signed-rank test was used to compare the diversity values 418 between the pneumonia samples and the two pneumotypes (BPT and SPT) we found that the 419 Chao 1 estimator was significantly lower in the pneumonia samples than in the BPT samples 420 (p-value=0.03304) and SPT (p-value=0.001337), similar to what was seen for the number of 421 observed OTUs compared to the BPT (p-value=0.01463) and SPT (p-value=0.01771) groups 422 ( Figure 7B) . The Shannon index was also higher for the BPT (p-value=0.0018) and SPT (p-423 value=0.0006683) samples than the pneumonia microbiomes. The healthy microbiome 424 compared to the antibiotic treated samples showed a higher abundance but not significant for 425 the Chao 1 (BPT vs antibiotics: p-value=0.34, SPT vs antibiotics: p-value=0.14), the number 426 of OTUs (BPT vs antibiotics: p-value=0.51, SPT vs antibiotics: p-value=0.28) and the 427 Shannon Index (BPT vs antibiotics: p-value=0.27, SPT vs antibiotics: p-value=0.14). Thus, 428 despite the small number of samples analysed it is clear that the bacterial species richness and 429 evenness during pneumonia and antibiotic treatment are lower than the diversity present in 430 healthy lungs. Low diversity has been also described in HIV-patients with acute pneumonia 431 and for other lung conditions such as cystic fibrosis [5, 18] , indicating that the overgrowth of 432 the pathogen leads to a reduction in the microbiome diversity. However, as for the 433 composition the antibiotics disturbed microbiome showed an intermediate diversity between 434 pneumonia and healthy pneumotypes representing probably a "transition state". 435 436 Carbohydrate metabolism, glycerophospholipid and nicotinate and nicotinamide 437 metabolism related genes are hallmarks of the pneumonia microbiome. The different 438 composition of the lung microbiomes of the healthy and the pneumonia patients might have 439 functional impact as different bacteria produce different metabolites and metabolise different 440 nutrients. We thus used the software PICRUSt to predict the metagenome of the different 441 microbiomes and compared them to identify functional differences. The LEfSe analysis was 442 applied to statistically compare the two groups according to the functional categories 443 represented in the KEGG pathways (Supplementary table 6) . Indeed, 28 metabolic pathways 444 were over-represented in pneumonia microbiomes, while 17 were more abundant in the 445 healthy microbiomes. In the microbiome of the pneumonia patients an over-abundance of 446 genes associated with bacterial motility such as flagella assembly or bacterial chemotaxis 447 were identified. Furthermore, a higher abundance of genes related to carbohydrate 448 metabolism like genes coding for the enzymes of the pentose phosphate pathway and the 449 pentose and glucuronate interconversions was present in the microbiome during pneumonia 450 and antibiotic therapy. This is similar to what was seen in metagenomes obtained from the 451 human gut under antibiotic therapy where metabolic pathways related to the carbohydrate 452 metabolism were also over-represented [42, 43] . According to gut-based studies an altered 453 microbiome due to antimicrobial therapy releases a different repertoire of sugars, which is 454 better exploited by opportunistic microorganisms [44] [45] [46] . The food web in the lung microbial 455 ecosystem is far from known, but the depletion of the normal members of the microbiome 456 seems to lead to an unbalance in the global metabolism of the community similar to what 457 occurs in the gut, and thereby favour the growth of opportunistic microorganisms. 458
In the microbiome of pneumonia patients, we also identified a higher abundance of 459 genes involved in the glycerophospholipid pathway (lipid metabolism) and the nicotinate and 460 nicotinamide metabolism. Alterations in glycerophospholipid levels have also been found in 461
BALs of HIV patients as well as a correlation of Staphylococacceae with a higher activity in 462 the nicotinate and nicotinamide metabolism [47] , similar to what we see in the pneumonia 463 related microbiomes analysed here. On the other hand, the microbiome of healthy people was 464 enriched in amino acid biosynthesis pathways. The activity of commensal bacteria in the 465 biosynthesis and metabolism of amino acids has been described in the human gut (for a 466 review see [48] ). Certain products of the metabolism of amino acids such as short-chain fatty 467 acids stimulate the immune system positively and have protective functions in the gut [49] . 468
Taken together, the Legionella induced pneumonia altered the microbiome, leading to 469 different metabolic activities that allow bacteria such as Staphylococacceae to become more 470 abundant and seem to decrease bacterial activities that produce short-chain fatty acids and 471 stimulate the immune system positively. 472 473 Ecological interactions between bacterial and fungal communities were observed in the 474 human lungs. Although the fungal community showed less changes than the bacterial 475 community during antibiotic treatment, we identified some parallel changes in diversity 476 between both groups (Supplementary figures 1, 2) . To get insight into the ecology of these 477 communities and their possible interactions, we used the Wilcoxon rank-test and compared 478 the diversity metrics distribution of both communities (Figure 8A) . As it seen in Figure 8A  479 the bacterial fraction showed a significant higher species diversity richness (Chao 1 test and 480 number of OTUs (p-value < 0.05)), but a more equitable distribution between the different 481 species in the fungal community was observed (p-value < 0.05). Thus, the bacterial 482 community is more variable in its composition and richer in species than the fungal 483 community, but the distribution is less even probably due to the dominance of the pathogen 484 and other opportunistic bacteria during infection and antibiotic therapy. To identify whether 485 there might be a relation between the diversity of the bacterial and the fungal communities, 486
Pearson correlation test comparisons between the alpha-diversity metrics were performed 487 ( Figure 8B) . A significant positive correlation of the richness (number of OTUs and Chao 1) 488 between bacteria and fungi was identified. The species distribution (based on Shannon Index) 489 between both communities showed a positive trend but it was not significant. This suggests a 490 cross-domain relation between both communities and a correspondence between different 491 bacterial and fungal species, but the relation is not strongly dependent on their abundances. 492
Due to these results we established a correlation network for the microbiome and 493 mycobiome and networks specific of each domain to identify putative associations between 494 members of each community (Figure 8 (bacteria-fungi), Supplementary figure 4A (bacteria-495 bacteria) and 4B (fungi-fungi)). Interestingly, we identified bacteria-bacteria, fungi-fungi and 496 bacteria-fungi associations, however, the relationships within each domain were the most 497 abundant (Figure 8) . Furthermore, certain associations identified might be very strong, as 498 they are maintained even when we analysed all possible interactions together (bacteria-fungi). 499
Examples are the Mycoplasma-Prevotella-Fusobacterium (bacteria) (Supplementary figure  500 4A) or the Morchella-Malassezia-Saccharomycetales (fungi) cluster (Supplementary figure  501   4B) . 502
We identified six main clusters in the mixed network. Cluster 1 was composed only of 503 fungi belonging to three different phyla, whereas cluster 2 was composed of bacteria and 504 fungi from different phyla. Most interestingly cluster 1 and 2 were connected through a 505 predicted interaction between Fusobacterium and Basidiomycota. For cluster 1 a second 506 interaction with cluster 6 containing fungi and bacteria was observed through interactions 507 between Saccharomyces, Zygomycota and Morchella and Malassezia (Figure 8C) . Cluster 6 508 is further connected with the bacterial cluster 5, which shows interactions with cluster 4 509 containing also only bacteria. These two bacterial clusters were enriched in Proteobacteria 510 and Actinobacteria. Cluster 3 was composed of bacteria and fungi and is the only one for which no interactions with other clusters of the 512 network were predicted. 513
To get more detailed information, which of the species are interacting, we performed 514 the network analysis again, but based on the OTUs identified in the bacterial and fungal 515 communities. In Supplementary figure 5 the 30 clusters obtained are represented in a 516 cladogram. Similarly, to the genus-based analysis, most of the clusters (25) were enriched in 517 bacteria or fungi but 5 were composed of bacteria and fungi. We observed a trend that 518 bacteria and fungi from the same phyla clustered. This co-occurrence of phylogenetically 519 closer related microorganisms may suggest cooperation and/or sharing the same niche instead 520 of competition. Associations between bacteria and fungi have been described in the literature 521 but little is known about their mechanisms of interaction. Similar to our results where an 522 association in a co-occurrence network of Fusobacterium and Prevotella was observed such 523 an interaction was also described for the lung microbiome of healthy individuals [4] . Cluster 524 6 included the genera Neisseria and Streptococcus, both have recently been proposed as 525 keystone species for the community structure of healthy neonatal airways [50] . 526
Taken together, the microbial and the fungal community present in the lungs of 527 humans are showing important interactions and seem to influence each other. Malasezzia, 528
Fusobacterium or Pseudomonas seem to be key in the ecosystem since they are connecting 529 different groups. 530 531 Whole genome sequencing of Legionella pneumophila strains isolated during disease and 532 antibiotic treatment. To follow the evolution of L. pneumophila during long term 533 pneumonia and antibiotic treatment we isolated and whole genome sequenced 17 534 L. pneumophila strains at different time points over the 2-month period of disease and 535 antibiotic treatment of patient A and 11 L. pneumophila strains during a 3-month period for 536 patient B. Surprisingly, mapping of the corresponding genomes to the earliest isolate did not 537 identify any genomic changes nor any chromosomal rearrangement (based on Pacbio 538 assemblies) between the first and the last isolates from patient A and B. Thus L. pneumophila 539 does not seem to evolve fast even when under antibiotics and immune system pressure. This 540 is in line with our previous report where we estimated a very low evolutionary rate of 0 . 71 541 SNPs/genome/year for L. pneumophila strains [51] . 542
We then searched specifically for mutations that are known to be associated with 543 fluoroquinolones, macrolides or rifampicin resistance, as patient A had been on long term 544 treatment with these antibiotics. However, we again did not identify any mutation. This result 545 was intriguing, as the antibiotic therapy did not eliminate the pathogen even after 42 days of 546 treatment. Also when the minimal extracellular concentrations inhibiting intracellular growth 547 (MIEC) were determined for levofloxacin, erythromycin and rifampicin the L. pneumophila 548 strain isolated from the pneumonia patient was not resistant to none of these antibiotics [16] . 549
As no antibiotic resistance was found for the L. pneumophila strain causing the pneumonia, 550 neither by whole genome analyses nor by susceptibility testing, the poor response to the 551 treatment might have been due to the presence of the abscess, which has constituted a 552 continuous source of infection. Indeed, the pneumonia for patient A was only cured after the 553 abscess was surgically removed 554 555 CONCLUSIONS 556
The analysis of the lung microbiome is still a quite new field of research but over the 557 past decade, we have learned that the lung is not sterile, even in healthy conditions. Most 558 analyses concentrated on lung diseases such as COPD, pulmonary cancer or cystic fibrosis. 559
Thus, the impact of the lung microbiome on disease development and outcome of bacterial 560 pneumonia in non-cystic fibrosis patients is nearly not known. Very recently the analyses of 561 the lung microbial community of adenovirus pneumonia, M. pneumoniae pneumonia and 562 tracheomalacia showed that each differed significantly with the dominance of the pathogen 563 within the microbiome [52] . Our comprehensive, longitudinal analyses of the lung 564 microbiome (bacteria, fungi, archaea and eukaryotes) of patients suffering for several month 565 from pneumonia due to L. pneumophila, and its comparison with healthy lung microbiomes 566 showed that infections engenders a highly disturbed lung microbiome. It is characterized by a 567 low species diversity, low abundance of many different taxa (specially from the phyla 568 Proteobacteria and Bacteroidetes) and the over-abundance of pathogenic and/or opportunistic 569 bacteria associated with lung infections such as Staphylococcus sp., Streptococcus sanguinis, 570
Cutibacterium acnes and Corynebacterium sp.. The strong dominance of the pathogen 571 overgrows and outcompetes the normal, resident microbiota. The low abundance of many of 572 these "healthy families" may be related to their susceptibility to antibiotics or to the fact that 573 these protective and/or beneficial microorganisms were absent or lowly abundant in the 574 patient's microbiome before infection. Similarly, to what has been described in other body 575 habitats, the antibiotic treated microbiome does not represent a healthy lung microbiome and 576 shows a higher abundance of resistant bacteria such as Staphylococcus or Enterococcus. 577
Very little is known about the role of fungi in the health of the lungs and the response 578 to infection. Here we show that the mycobiome follows a more stable dynamics during 579 infection and antibiotic treatment with Ascomycota and Basidiomycota as the most abundant 580 phyla. The "gap" in the fungi databases does not allow an accurate classification of fungi at 581 low taxonomic levels. Thus, a great portion of the diversity at genus and family levels 582 remains unknown so far. The identification of correlations in the diversity and composition of 583 bacterial and fungal communities in the lungs of the here analysed individuals may suggest an 584 ecological relationship between both communities that could be key for the restoration of the 585 microbiome after the cessation of the disease and the antimicrobial therapy. 586
Interestingly, archaea might also play an important role in the lung microbiota 587 community and in disease severity or outcome, as suggested by the presence of several 588 different archaea and in particular of Methanobrevibacter smithii in all our lung 589 microbiomes.Corrections version 6 Furthermore, we showed here that amoeba and other 590 protozoa are present in the lung microbiome. This might partly be due to the fact that 591
Legionella-infected amoeba had been inhaled we identified several different protozoa, thus it 592 seems that the lung microbiota also contains a community of protozoa. Whether protozoa are 593 part of the healthy microbiome or are only present in Legionella associated pneumonia 594 patients, needs to be studied further. 595
Recently, a 3D model of human lungs was developed and the microbiome and 596 metabolome obtained from a cystic fibrosis lung was mapped [53] . This study showed how 597 the microorganisms occupy different regions of the lung, and how drugs penetrate the lungs at 598 many different levels. Thus, the response of the microbiome to infection and the antibiotics 599 depends on many factors, including the microbial composition before the treatment, the type 600 of antibiotic and its pharmacology properties (time of retention, doses, diffusion, etc), the 601 immunological status of the individual and the repertoire of resistance genes in the 602 microbiome. Here we show that also interactions between fungi, archaea and protozoa need to 603 be considered in the outcome of the infection and antibiotic therapy. Whole genome sequencing. To analyse the intra-patient evolution of L. pneumophila, a total 621 of 17 isolates from patient A and 11 from patient B during different stages of the antibiotic 622 treatment were collected and sequenced. The isolates from patient A were taken at days 4, 5, 623 10, 13, 14 (2 isolates), 16, 22, 26, 29, 30, 31, 33, 34, 36, 39 and 42 during hospitalization and 624 the isolates of patient B were taken at days 0 (6 isolates) and 69 (5 isolates) and sequenced on 625 a Illumina Nextseq500 (150 bp paired-end) machine. Reads were trimmed for low quality and 626 adapter removing using trimmomatic 0.36 [54] . Trimmed reads were assembled using 627
SPAdes [55] . Polymorphisms between isolates from the same Patient were searched by 628 mapping the trimmed reads on the assembly of the 1 st isolate using BWA v0.7.12 [56] . Pacbio 629 sequencing was performed by GATC Biotech. Genomes were assembled using the SMRT 630 Analysis software suite. 631
Mutations in the genes rplD and rpIV encoding ribosomal proteins, as well as in the 632 domain V of 23S rRNA where mutations associated with macrolide resistances may occur, 633 were analysed. Possible mutations associated to fluoroquinolone resistance in the genes gyrA, 634 gyrB (topoisomerase II) and parC (topoisomerase IV) and mutations conferring rifampicin 635 resistance in the rpoB gene encoding for the β subunit of the RNA polymerase were searched. 636
Trimmed reads were mapped on the different gene targets using BWA v0.7.12 and variant 637 calling was done using the Naïve variant caller v0.0.4 [56] . For characterizing the mycobiome we amplified the ITS region by using the ITS1/ITs2 651 primers. Forward primer (5'-CTTGGTCATTTAGAGGAAGTAA-3') with adaptor (5'-652 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3') and reverse primer (5'-653 GCTGCGTTCTTCATCGATGC-3') with adaptor (5'-GTCTCGTGGGCTCGGAG 654 ATGTGTATAAGAGACAG-3'). We used the same reaction mix and PCR conditions as 655 described above, but 30 cycles. All the amplicons were checked by electrophoresis in agarose 656 gel (1.4%). 657
To characterize the archaeal microbiome a commonly used region of the 16S rRNA to 658 detect archaea was amplified by using the primers: 787F (5'-659
Bacterial density determination. Quantitative real-time PCR (qPCR) was performed to 676 quantify total bacteria and fungi in the samples based on the 16SrRNA gene. We used the 677 forward primer 520F (5'-AYTGGGYDTAAAGNG-3') and the reverse primer 802R (5'-678 TACNVGGGTATCTAATCC-3'). Standard curves were estimated by using serial 10-fold 679 dilutions of purified and quantified amplicons. The PCR was prepared in a final volume of 20 680 µL by adding 10 µL of the SYBR Green QPCR Master Mix 5X (Applied Biosystems), 0. program uses the information available for the marker gene to predict gene family 705 abundances. We used the GreenGenes database (version 13.5) implemented in the Galaxy 706 Server (http://huttenhower.sph.harvard.edu/galaxy/) for the prediction and the KEGG 707
Orthologs annotation for the output. 708 709 Ecological and statistical analysis. We estimated the microbial richness and diversity of the 710 samples by calculating the total number of OTUs, the Chao 1 estimator [64] , and the Shannon 711 diversity index (Shannon, n.d.). All these analyses were based on the core diversity analysis 712 script implemented in the QIIME pipeline using the same depth for all the samples. The 713
16SrRNA abundance table was rarefied at 60,000 reads per sample and the ITS at 6,000 714 according to the sequencing effort. A hierarchical clustering analysis based on Bray-Curtis 715 dissimilarity was also applied to compare the microbial composition between the different 716 samples. 717
To statistically compare the diversity estimators between groups of samples, we used 718 the Wilcoxon signed-rank test. Correlation analyses of the diversity and composition of the 719 microbiome and mycobiome were applied based on the Pearson method. We used a 720 multivariate ANOVA based on dissimilarities (Adonis) to test the influence of external 721 variables in explaining differences in composition between different groups of samples. We 722 used the Vegan package of the R program for this analysis [65] . All analyses were based on 723 the R software considering p-values below 0.05 as significant [66] . The linear discriminant 724 analysis (LDA) effect size (LEfSe) analysis was applied to identify those taxa and genes 725 characterizing the different groups of samples [67] . We considered taxa as discriminative of 726 groups when the LDA score was higher than 2. 727 728 Co-occurrence network analysis. We calculated co-occurrence networks for the 16SrRNA 729 and the ITS OTU data. The networks were based on the OTU-rarefied abundance tables 730 collapsed at genus level. We used SparCC to estimate the correlation coefficients between the 731 genera, using 500 bootstraps from the genus-table to estimate the "two-sided" p-values [68] . 732
The correlation matrix was filtered to keep significant correlations based on a p-value lower 733 than 0.01 and converted in a network by using the igraph package implemented in R software 734
[69]. The igraph package was used to display the network using a force-directed layout, 735
representing the edges the correlation coefficients between taxa. We detected groups of taxa 736 more connected between then and with fewer connections with other groups by using the 737 Newman-Girvan algorithm also implemented in the igraph package. 
